Avacta Group PLC

Here is the public summary page for Avacta Group PLC. Please login to see the complete information for Avacta Group PLC including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Avacta Group PLC stacks up relative to its peers.


Darwin Score+16
TickerAVCT
Latest Price0.48 GBP as of close on 15-Aug-2025
3 Month price range0.28 to 0.55 GBP
Market Capitalisation184.81Mn GBP
CountryUK
RegionEurope
Economic SectorHealth Care
Business SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryBiotechnology
Sub-IndustryBiotechnology
Description
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
See More ...
Company URLhttps://avacta.com
See Darwins Full Analysis for Avacta Group PLC

Tell Me About

Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Avacta Group PLC. Further information and full detail is available when you login.

TMA PartFocus of AnalysisTMA Score
PriceAnalysis of performance, trend, RSI, OBV and moving averages+24
SentimentNews and Candle Patterns. 0
FundamentalsAnalyst Ratings, Valuation and Dividend analysis.-6
FlowInstitutional, Fund and Insider buying and selling.0
ModelsForecast models.-2

Alerts

There are 3 live alerts for Avacta Group PLC.


Peer Comparison

There are 29 peers of Avacta Group PLC.
Asset NameIndustry GroupPerf(20d)%Asset Score
4BASEBIO UK SOCIETAS (4BB)Biotechnology-8.6-14
Abingdon Health Plc (ABDX)Biotechnology0-25
Alliance Pharma plc (APH)Biotechnology+0.8+31
Angle PLC (AGL)Biotechnology-15.4-18
Aptamer Group PLC (APTA)Biotechnology+80.3+12
Arecor Therapeutics PLC (AREC)Biotechnology+29.6+6
BSF Enterprise Plc (BSFA)Biotechnology+1.2-16
Benchmark Holdings Plc (BMK)Biotechnology-10.7-18
Beximco Pharmaceuticals Limited (BXP)Biotechnology+20.3+32
BiVictriX Therapeutics PLC (BVX)Biotechnology+21.2+2
Bioventix (BVXP)Biotechnology-15.6+2
Celadon Pharmaceuticals PLC (CEL)Biotechnology0-8
Chill Brands Group PLC (CHLL)Biotechnology-2.3-21
Cizzle Biotechnology Holdings PLC (CIZ)Biotechnology-18.8-15
Destiny Pharma PLC (DEST)Biotechnology-7.7-30
Diaceutics PLC (DXRX)Biotechnology+7.0+17
Evgen Pharma PLC (EVG)Biotechnology-8.6-7
Faron Pharmaceuticals Oy (FARN)Biotechnology+2.4+12
Genflow Biosciences plc (GENF)Biotechnology-10.7-27
Genincode PLC (GENI)Biotechnology-26.3-21
Genus PLC (GNS)Biotechnology+8.3+20
Haleon PLC (HLN)Biotechnology0+4
Ondine Biomedical Inc (OBI)Biotechnology+25.0+14
Oxford BioMedica PLC (OXB)Biotechnology+33.6+41
Oxford Nanopore Technologies PLC (ONT)Biotechnology+43.5+8
Physiomics PLC (PYC)Biotechnology-10.5-9
Shield Therapeutics PLC (STX)Biotechnology+59.2+20
e-therapeutics plc (ETX)Biotechnology-28.0-4
genedrive plc (GDR)Biotechnology-39.3-8

Share Share on Facebook Share on Twitter Share on Threads Share on LinkedIn